Company: MDCXW
Filing Date: 2025-11-19
Form Type: S-1
Source: 0001062993-25-016962
Chunk: 213

Company: Medicus Pharma Ltd.
Filing Date: 2025-11-19
Form: S-1
Chunk 213
---
 shareholder, broker, dealer, underwriter, or agent relating to the sale or distribution of the common shares being offered for sale by this prospectus.

Beneficial ownership is determined in accordance with Rule 13d-3(d) promulgated by the SEC under the Exchange Act and includes common shares with respect to which the Selling Shareholder has sole or shared voting and investment power. The percentage of common shares beneficially owned by the Selling Shareholder prior to the offering shown in the table below is based on an aggregate of 22,029,144 common shares outstanding on November 7, 2025.

We have determined beneficial ownership in accordance with the rules of the SEC.

|                            |     |   Number of Common 
             Shares 
 Beneficially Owned |     |         |     |   Maximum Number of 
 Common Shares Being 
          Offered(2) |           | Common Shares Beneficially Owned After the 
             Offered Common Shares Are Sold |         |   |
| Name of Selling            
 Shareholder                |     |          Number(1) |     | Percent |     |                     | Number(3) |                                            | Percent |   |
| Armistice Capital, LLC (4) |     |          2,740,000 |     | 12.4%   |     |           2,680,000 |           |                                     60,600 |         | * |

*Less than one percent.

(1)Represents (i) 2,680,000 common shares underlying Private Warrants we issued to the Selling Shareholder in consideration for entering into the Warrant Inducement Agreement and (ii) an additional 60,600 common shares deemed beneficially owned by the Selling Shareholder. The number of common shares represented as being beneficially owned does not give effect to the Beneficial Ownership Limitation (as defined in the Private Warrant) which prohibits the Selling Shareholder from exercising Private Warrants if, immediately after giving effect to the issuance of common shares issuable upon exercise of the Private Warrants, the Selling Shareholder’s beneficial ownership would equal or exceed 4.99% (or, upon election, 9.99%) of the issued and outstanding common shares.

(2)Represents 2,680,000 common shares underlying Private Warrants we issued to the Selling Shareholder in consideration for entering into the Warrant Inducement Agreement.

<div align='center'>148</div>

(3)Assumes the sale of all common shares being